# SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation

> **NCT04631705** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Cologne** · enrollment: 45 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** DZIF-10c
- **BIOLOGICAL:** DZIF-10c
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04631705
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-14
- **Primary completion:** 2021-09-23
- **Final completion:** 2021-09-23
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** Change in viral variant epidemiology
- **Last updated:** 2024-10-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04631705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04631705, "SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04631705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*